TVTX — Travere Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $5.09bn
- $490.73m
Brief: Travere Therapeutics Q1 EPS USD -0.47 Vs. IBES Estimate USD -0.54
Brief: Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy
Brief: CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy
U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital
U.S. STOCKS ON THE MOVE-Gold miners, Blackstone, PepsiCo
Travere rises on co's marketing application for kidney disease drug
Brief: Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS
U.S. RESEARCH ROUNDUP-Blue Owl Capital, Insulet, Unity Software
U.S. RESEARCH ROUNDUP-Blue Owl Capital, Insulet, Unity Software
Travere Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Travere Therapeutics Q4 EPS USD -0.73 Vs. IBES Estimate USD -0.56
Travere Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Guggenheim raises PT on Travere Therapeutics
Brief: Travere Therapeutics Provides Corporate Update And 2025 Outlook
U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart
Brief: Travere Therapeutics Prices Public Offering Of 7.81 Mln Shares At $16.00 Each
Travere Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Travere Therapeutics Entered Amended & Restated Agreement Of Upto $100 Million In Common Stock Offering